ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 102 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2016. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | +27.0% | 206,156 | +80.4% | 0.00% | – |
| Q2 2023 | $159 | -100.0% | 114,300 | -60.1% | 0.00% | -100.0% |
| Q3 2022 | $1,921,000 | -21.6% | 286,700 | -25.6% | 0.00% | 0.0% |
| Q2 2022 | $2,451,000 | +25.1% | 385,300 | -8.7% | 0.00% | +50.0% |
| Q1 2022 | $1,959,000 | -62.3% | 422,200 | +197.5% | 0.00% | -50.0% |
| Q3 2019 | $5,202,000 | -52.9% | 141,900 | -40.3% | 0.00% | -60.0% |
| Q2 2019 | $11,049,000 | +40.7% | 237,500 | +21.4% | 0.01% | +42.9% |
| Q1 2019 | $7,853,000 | +854.2% | 195,595 | +992.7% | 0.01% | +600.0% |
| Q4 2018 | $823,000 | +13.2% | 17,900 | +23.4% | 0.00% | 0.0% |
| Q3 2017 | $727,000 | -83.5% | 14,500 | -95.5% | 0.00% | -87.5% |
| Q3 2016 | $4,415,000 | +142.6% | 318,800 | +196.3% | 0.01% | +166.7% |
| Q1 2016 | $1,820,000 | -77.4% | 107,600 | -70.2% | 0.00% | -83.3% |
| Q4 2015 | $8,040,000 | – | 361,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |